Clinical trial · Interventional
Trial of BMS-986012 in Combination With Platinum and Etoposide
A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
NCT02815592CI-TRIAL-00080417completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BMS-986012 | Drug | — | UNRESOLVED |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Platinum | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Experimental Arm 1
- description
- BMS-986012/Cisplatin/Etoposide
- interventionNames
- Drug: BMS-986012
- Drug: Cisplatin
- Drug: Etoposide
- type
- EXPERIMENTAL
- label
- Experimental Arm 2
- description
- BMS-986012/Carboplatin/Etoposide
- interventionNames
- Drug: BMS-986012
- Drug: Etoposide
- Drug: Carboplatin
- type
- EXPERIMENTAL
- label
- Experimental Arm 3A
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Male and Females 18 years of age or older * Pulmonary SCLC documented by histology or cytology * Extensive disease (Stage IV) SCLC * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: * Prior systemic therapy for lung cancer * Symptomatic brain metastases * Grade 2 peripheral neuropathy * Active or chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV * Other active malignancies or prior malignancy within 2 years Other protocol defined inclusion/exclusion criteria could apply
References
Publications (0)
Data not yet available
No reference posted for this study.